Abstract
The double suicide gene therapy strategy combining herpes simplex virus type-1 thymidine kinase (HSV-1 TK) and cytosine deaminase (CD) with ganciclovir (GCV) and 5-fluorocytosine (5-FC) had been carried out in a phase I clinical trail for prostate cancer. The objective of the present study was to ascertain whether co-expression of HSV-1 TK, CD, and uracil phosphoribosyltransferase (UPRT) in conjunction with GCV and 5-FC treatment, a triple suicide gene therapy strategy, would be more effective at killing and radiosensitizing prostate cancer cells than double suicide gene therapy.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International Journal of Radiation Oncology*Biology*Physics
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
